Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announced that it has initiated a structured transaction process regarding the so-called GTX platform, consisting of therapeutic peptides based on the endogenous protein alpha-1-microglobulin (A1M), together with related intellectual property and other relevant assets (the “GTX platform”).
As announced on 10 June 2026, Guard Therapeutics has entered into a conditional agreement regarding a reverse takeover of Disruptive Pharma Holding AB (publ). The GTX platform is not considered strategically aligned with the business intended to be conducted following completion of the proposed transaction. Against this background, the Company has initiated a process to evaluate the potential for a transaction relating to the GTX platform.
Such a transaction may be structured as an outright sale, out-licensing, or another commercial arrangement. Qualified parties are invited to submit indicative offers for the GTX platform, preferably no later than 30 June 2026.
The Company’s ambition is, subject to relevant conditions being met, to complete the process prior to the extraordinary general meeting planned to be held on 20 July 2026. However, there can be no assurance that the process will result in a transaction or that any transaction will be completed within this timeframe.
“The GTX platform falls outside the strategic focus of the business to be pursued following the planned reverse takeover of Disruptive Pharma. The Board of Directors and management therefore consider it appropriate to explore the possibility of completing an accelerated transaction relating to the GTX platform,” said Tobias Agervald, CEO of Guard Therapeutics.
The GTX Platform comprises a portfolio of peptides based on A1M, along with associated intellectual property. The lead candidate, GTX-86, has, according to the Company’s internal criteria, achieved the requirements for candidate nomination and further preclinical development.